Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialYunpeng Yang, Wenfeng Fang, Ying Cheng et al.|Signal Transduction and Targeted Therapy|2023Cited by 32
The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).Wěi Li, Caicun Zhou, Nong Yang et al.|Journal of Clinical Oncology|2022Cited by 12